Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Primary Purpose
Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
saracatinib
Sponsored by
About this trial
This is an interventional treatment trial for Invasive Thymoma and Thymic Carcinoma
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed invasive thymoma or thymic carcinoma, meeting the following criteria:
- Relapsed or refractory disease
- Metastatic, unresectable disease
- Locally invasive disease allowed provided it is not resectable and has been previously treated
- Progressive disease
- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan
- Must have received >= 1 prior chemotherapy regimen
- No active brain metastases
- Patients with previously treated brain metastases (surgical resection or radiotherapy) are eligible provided they have documented stable brain disease for >= 1 month after completion of therapy and are asymptomatic
- ECOG performance status 0-2
- Leukocytes >= 3,000/mm^3
- ANC >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin > 9 g/dL
- Serum bilirubin < 2.0 times upper limit of normal (ULN)
- Transaminases =< 2.5 times ULN (< 5.0 times ULN if liver metastasis is present)
- Serum creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min
- Urine protein:creatinine ratio < 0.5 OR urine protein < 1,000 mg by 24-hour urine collection
- QTc < 460 msec
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after completion of study treatment
- No known history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
- No other malignancies within the past 3 years, except curatively treated in situ carcinoma of the cervix or completely resected nonmelanoma skin cancer
- No concurrent active malignancies other than thymic malignancy
- No condition that impairs the ability to swallow AZD0350 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease)
No cardiac dysfunction including, but not limited to, any of the following:
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- History of ischemic heart disease
- Myocardial infarction within the past year
- No QTc prolongation or other significant ECG abnormalities
- No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 150 mm Hg or diastolic BP ≥ 95 mm Hg)
No evidence of severe or uncontrolled systemic conditions that would make it undesirable to participate in the study or that would jeopardize compliance with the study, including any of the following:
- Severe hepatic impairment
- Interstitial lung disease (bilateral, diffuse, or parenchymal lung disease)
- Unstable or uncompensated respiratory condition
- Unstable or uncompensated cardiac condition
No uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Mental health issues or social circumstances that would limit compliance with study requirements
- No prior src inhibitors
- At least 4 weeks since prior systemic therapy (6 weeks for carmustine or mitomycin C)
- At least 8 weeks since prior immunotherapy
- At least 4 weeks since prior octreotide
- Concurrent octreotide for pure red cell aplasia allowed provided patient continues on the same dose and schedule, has had a response to this drug, and has demonstrated progressive thymoma by radiography or physical exam
- At least 4 weeks since prior surgery and recovered
- At least 4 weeks since prior investigational agents
- At least 4 weeks since prior radiotherapy to measurable disease sites (2 weeks for palliative radiotherapy to metastatic sites) and recovered
- At least 7 days since prior and no concurrent active CYP3A4 agents or substances
- No other concurrent investigational or anticancer agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
- Concurrent steroids allowed for treatment of a pre-existing autoimmune disorder or as antiemetic therapy
Sites / Locations
- Stanford University Hospitals and Clinics
- Indiana University Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Arm I
Arm Description
Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Outcomes
Primary Outcome Measures
Objective Response Rate (Complete and Partial Response)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The objective response rate will be reported by each disease classification. The percent of patients having an objective response (complete or partial response) will be estimated with a 95% exact binomial confidence interval for the percent of patients receiving drug. Note: there were no objective responses in this trial.
Secondary Outcome Measures
Progression-free Survival
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. This will be examined in an exploratory fashion using Kaplan-Meier estimates. Time until progression, death or last evaluation will be calculated. If a patient did not progress or die, they will be censored at their last evaluation in the analysis.
Overall Survival
Will be examined in an exploratory fashion using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.
Disease Control Rate
Will be examined in an exploratory fashion using Kaplan-Meier estimates. Disease control rate defined as complete response (CR) + partial response (PR) + stable disease (SD). The length of time until progression or until last evaluation will be calculated. For patients who did not progress, they will be censored in the analysis.
Expected Toxicities Including Skin Rashes and Diarrhea
Number of patients who had toxicities classified as skin rashes and diarrhea within the adverse events.
Full Information
NCT ID
NCT00718809
First Posted
July 18, 2008
Last Updated
June 5, 2015
Sponsor
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT00718809
Brief Title
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Official Title
Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Terminated
Study Start Date
June 2008 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)
4. Oversight
5. Study Description
Brief Summary
This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the objective response rate (complete response and partial response) in patients with relapsed or refractory thymoma or thymic carcinoma treated with AZD0530.
SECONDARY OBJECTIVES:
I. To evaluate the toxicity of AZD0530 in these patients. II. To evaluate the progression-free survival of these patients. III. To evaluate the overall survival of these patients. IV. To evaluate the disease control rate, defined as complete response, partial response, and stable disease, in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma, Stage IVB Thymoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm I
Arm Type
Experimental
Arm Description
Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
saracatinib
Other Intervention Name(s)
AZD0530
Intervention Description
Given orally
Primary Outcome Measure Information:
Title
Objective Response Rate (Complete and Partial Response)
Description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The objective response rate will be reported by each disease classification. The percent of patients having an objective response (complete or partial response) will be estimated with a 95% exact binomial confidence interval for the percent of patients receiving drug. Note: there were no objective responses in this trial.
Time Frame
Up to 5 years
Secondary Outcome Measure Information:
Title
Progression-free Survival
Description
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. This will be examined in an exploratory fashion using Kaplan-Meier estimates. Time until progression, death or last evaluation will be calculated. If a patient did not progress or die, they will be censored at their last evaluation in the analysis.
Time Frame
Time from the date of registration to the first reported outcome event, assessed up to 5 years
Title
Overall Survival
Description
Will be examined in an exploratory fashion using Kaplan-Meier estimates. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis.
Time Frame
Time from the date of registration to last reported date of survival, assessed up to 5 years
Title
Disease Control Rate
Description
Will be examined in an exploratory fashion using Kaplan-Meier estimates. Disease control rate defined as complete response (CR) + partial response (PR) + stable disease (SD). The length of time until progression or until last evaluation will be calculated. For patients who did not progress, they will be censored in the analysis.
Time Frame
Up to 5 years
Title
Expected Toxicities Including Skin Rashes and Diarrhea
Description
Number of patients who had toxicities classified as skin rashes and diarrhea within the adverse events.
Time Frame
Up to 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed invasive thymoma or thymic carcinoma, meeting the following criteria:
Relapsed or refractory disease
Metastatic, unresectable disease
Locally invasive disease allowed provided it is not resectable and has been previously treated
Progressive disease
Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan
Must have received >= 1 prior chemotherapy regimen
No active brain metastases
Patients with previously treated brain metastases (surgical resection or radiotherapy) are eligible provided they have documented stable brain disease for >= 1 month after completion of therapy and are asymptomatic
ECOG performance status 0-2
Leukocytes >= 3,000/mm^3
ANC >= 1,500/mm^3
Platelet count >= 100,000/mm^3
Hemoglobin > 9 g/dL
Serum bilirubin < 2.0 times upper limit of normal (ULN)
Transaminases =< 2.5 times ULN (< 5.0 times ULN if liver metastasis is present)
Serum creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min
Urine protein:creatinine ratio < 0.5 OR urine protein < 1,000 mg by 24-hour urine collection
QTc < 460 msec
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 30 days after completion of study treatment
No known history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
No other malignancies within the past 3 years, except curatively treated in situ carcinoma of the cervix or completely resected nonmelanoma skin cancer
No concurrent active malignancies other than thymic malignancy
No condition that impairs the ability to swallow AZD0350 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease)
No cardiac dysfunction including, but not limited to, any of the following:
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
History of ischemic heart disease
Myocardial infarction within the past year
No QTc prolongation or other significant ECG abnormalities
No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 150 mm Hg or diastolic BP ≥ 95 mm Hg)
No evidence of severe or uncontrolled systemic conditions that would make it undesirable to participate in the study or that would jeopardize compliance with the study, including any of the following:
Severe hepatic impairment
Interstitial lung disease (bilateral, diffuse, or parenchymal lung disease)
Unstable or uncompensated respiratory condition
Unstable or uncompensated cardiac condition
No uncontrolled illness including, but not limited to, any of the following:
Ongoing or active infection
Mental health issues or social circumstances that would limit compliance with study requirements
No prior src inhibitors
At least 4 weeks since prior systemic therapy (6 weeks for carmustine or mitomycin C)
At least 8 weeks since prior immunotherapy
At least 4 weeks since prior octreotide
Concurrent octreotide for pure red cell aplasia allowed provided patient continues on the same dose and schedule, has had a response to this drug, and has demonstrated progressive thymoma by radiography or physical exam
At least 4 weeks since prior surgery and recovered
At least 4 weeks since prior investigational agents
At least 4 weeks since prior radiotherapy to measurable disease sites (2 weeks for palliative radiotherapy to metastatic sites) and recovered
At least 7 days since prior and no concurrent active CYP3A4 agents or substances
No other concurrent investigational or anticancer agents
No concurrent combination antiretroviral therapy for HIV-positive patients
Concurrent steroids allowed for treatment of a pre-existing autoimmune disorder or as antiemetic therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Loehrer
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University Hospitals and Clinics
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Indiana University Medical Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
26009269
Citation
Gubens MA, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, Wakelee HA. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer. 2015 Jul;89(1):57-60. doi: 10.1016/j.lungcan.2015.04.008. Epub 2015 Apr 25.
Results Reference
derived
Learn more about this trial
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
We'll reach out to this number within 24 hrs